Landos Biopharma, Inc.

Landos did not report quarterly revenue, EPS, or gross margin on this call, as it was a corporate update rather than an earnings release. Management said the company has over $100 million in cash and believes that cash carries it through the next two years. On guidance, Landos said it will no longer provide timing guidance for top-line results on the Crohn’s Phase 2 study, the NX-13 Phase 1b study, or most preclinical programs, and it withdrew previous guidance on additional IND filings. The company still expects LABP-104 Phase 1 data in the second quarter, and plans to communicate updates on Omilancor Phase 2b design early next year, once sample size and trial design are worked out.

Chris Garabedian framed the reset as a deliberate move to maximize long-term value by narrowing focus on the most important clinical work. He emphasized that Landos now has seven product candidates across three mechanisms, but the key priority is to choose the right advanced development strategy for the three clinical assets. His tone was confident but cautious: he repeatedly said the company wants to avoid premature commitments until trial design, population selection, and dose strategy are better supported by the data.

Patricia Bitar did not provide a detailed financial presentation on the call, and no revenue or EPS figures were discussed. The main financial point came from management’s comments that Landos has over $100 million in cash and expects that to fund operations for roughly the next two years. Tim Mayleben said capital will be deployed primarily toward the refocused clinical-stage programs, with more detail to come over the next couple of quarters as plans are refined.

Analysts pressed on cash use, Omilancor’s target population, dose selection, and whether the company would wait for a permanent CEO before finalizing trial changes. Management said it will not wait arbitrarily for a new CEO to act on study design, and that it is already working with advisors and the board. On Omilancor UC, they said the moderate-patient subset looked stronger than the mild group, dose response was not clear, and additional data may help determine whether a higher dose or different population is optimal. They also confirmed both Crohn’s studies are enrolling, but the Mount Sinai/NIH mechanistic study is not seen as gating a pivotal program.